These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 6342687)

  • 41. [Tissue plasminogen activator: mechanism of action and thrombolytic properties].
    Páramo JA; Collen D
    Sangre (Barc); 1984; 29(4-C):767-73. PubMed ID: 6393389
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluation of epithelial tissue plasminogen activator as a thrombolytic agent in a rabbit model of venous thrombosis.
    Electricwala A; Emeis JJ; Atkinson T
    J Pharmacol Exp Ther; 1986 Jul; 238(1):254-8. PubMed ID: 2425075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
    Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
    J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonradical excited oxygen species induce selective thrombolysis in vivo.
    Stief TW
    Thromb Res; 1991 May; 62(3):147-63. PubMed ID: 1716380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system.
    Mattsson C; Nyberg-Arrhenius V; Wallén P
    Thromb Res; 1981 Mar; 21(6):535-45. PubMed ID: 7022741
    [No Abstract]   [Full Text] [Related]  

  • 46. Relationship between gender difference in intravascular aggregation of platelets and the fibrinolytic pathway in the rat.
    Oyekan AO; Botting JH
    Arch Int Pharmacodyn Ther; 1991; 313():176-92. PubMed ID: 1816761
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Thrombolytic effect of urokinase upon various methods of administration into the body].
    Andreenko GV; Serebriakova TN; Podorol'skaia LV; Afanasenko GA; Liaginskiĭ AV; Raevskaia AK
    Vopr Med Khim; 1992; 38(1):44-6. PubMed ID: 1441294
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhancement of fibrinolytic and thrombolytic potential in the rat by treatment with an anabolic steroid, furazabol.
    Kumada T; Abiko Y
    Thromb Haemost; 1976 Nov; 36(2):451-64. PubMed ID: 1036845
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pharmacologic principles of fibrinolytic therapy].
    Markwardt F
    Z Gesamte Inn Med; 1987 Sep; 42(17):473-8. PubMed ID: 3318182
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
    Collen D; Stassen JM; Marafino BJ; Builder S; De Cock F; Ogez J; Tajiri D; Pennica D; Bennett WF; Salwa J
    J Pharmacol Exp Ther; 1984 Oct; 231(1):146-52. PubMed ID: 6541693
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
    Lijnen HR; De Wreede K; Demarsin E; Collen D
    Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization and antithrombotic action of tissue plasminogen activator.
    Bergqvist D; Nilsson IM; Pandolfi M
    Experientia; 1984 Jan; 40(1):67-8. PubMed ID: 6229416
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Fibrinolytic properties and thrombolytic effect of a novel fibrinolytic enzyme from Streptomyces sp. Y405].
    Wang M; Wang J; Shao M; Wang M; Wang Y
    Yao Xue Xue Bao; 1998 Jul; 33(7):481-5. PubMed ID: 12016879
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of the fibrinolytic system in corneal angiogenesis.
    Vogten JM; Reijerkerk A; Meijers JC; Voest EE; Borel Rinkes IH; Gebbink MF
    Angiogenesis; 2003; 6(4):311-6. PubMed ID: 15166500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Synthetic compounds with fibrinolytic and thrombolytic activity. I. Pharmacologic observations].
    Desnoyers P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(3):351-6. PubMed ID: 63421
    [No Abstract]   [Full Text] [Related]  

  • 56. [Thrombolytic properties of the heparin-tissue plasminogen activator complex and its effect on the fibrinolytic and coagulating systems of the blood in animals].
    Shimonaeva EE; Andreenko GV
    Vopr Med Khim; 1988; 34(1):59-62. PubMed ID: 3130724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pro-urokinase: physiochemical properties and promotion of its fibrinolytic activity by urokinase and by tissue plasminogen activator with which it has a complementary mechanism of action.
    Gurewich V
    Semin Thromb Hemost; 1988 Jan; 14(1):110-5. PubMed ID: 3127884
    [No Abstract]   [Full Text] [Related]  

  • 58. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator.
    Juhan-Vague I; Stassen JM; Alessi MC; Elias A; Aillaud MF; Serradimigni A; Collen D
    Semin Thromb Hemost; 1989 Oct; 15(4):390-4. PubMed ID: 2554499
    [No Abstract]   [Full Text] [Related]  

  • 60. Changes in the fibrinolytic components of cultured human umbilical vein endothelial cells induced by endotoxin, tumor necrosis factor-alpha and interleukin-1alpha.
    Orbe J; Chordá C; Montes R; Páramo JA
    Haematologica; 1999 Apr; 84(4):306-11. PubMed ID: 10190943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.